Dianon Systems, Inc.
Records under this name other than patents Dianon Systems, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,171,796 | Biomarkers and targets for diagnosis prognosis and management of prostate disease Formerly held Term ended Term ended Aug 3, 2019 · From the USPTO record | Term ended | Term ended Aug 3, 2019 | From the USPTO record |
| US 6,156,515 | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer Formerly held Term ended Term ended Feb 9, 2019 · From the USPTO record | Term ended | Term ended Feb 9, 2019 | From the USPTO record |
| US 6,218,529 | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer Formerly held Term ended Term ended Jun 12, 2018 · From the USPTO record | Term ended | Term ended Jun 12, 2018 | From the USPTO record |
| US 6,190,857 | Diagnosis of disease state using MRNA profiles in peripheral leukocytes Formerly held Term ended Term ended Mar 24, 2018 · From the USPTO record | Term ended | Term ended Mar 24, 2018 | From the USPTO record |
| US 6,025,128 | Prediction of prostate cancer progression by analysis of selected predictive parameters Formerly held Term ended Term ended Feb 15, 2017 · From the USPTO record | Term ended | Term ended Feb 15, 2017 | From the USPTO record |
| US 7,332,270 | Diagnosis of disease state using mRNA profiles in peripheral leukocytes Formerly held Lapsed on the fee record Ended Feb 19, 2016 · From the USPTO record | Lapsed on the fee record | Ended Feb 19, 2016 | From the USPTO record |
| US 7,993,830 | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer Formerly held Lapsed on the fee record Ended Aug 9, 2015 · From the USPTO record | Lapsed on the fee record | Ended Aug 9, 2015 | From the USPTO record |
| US 6,463,438 | Neural network for cell image analysis for identification of abnormal cells Formerly held Lapsed on the fee record Ended Oct 8, 2014 · From the USPTO record | Lapsed on the fee record | Ended Oct 8, 2014 | From the USPTO record |
| US 6,369,195 | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer Formerly held Lapsed on the fee record Ended Apr 9, 2014 · From the USPTO record | Lapsed on the fee record | Ended Apr 9, 2014 | From the USPTO record |
| US 6,140,065 | Methods for diagnosing benign prostatic diseases and prostatic adenocarcinoma using an algorithm Lapsed on the fee record Ended Oct 31, 2008 · From the USPTO record | Lapsed on the fee record | Ended Oct 31, 2008 | From the USPTO record |